fishing game genshin
Fireweed Metals Corp. awarded up to C$35.4 M in joint US-Canadian government funding to advance Mactung and essential Infrastructure to unlock the critical minerals district at Macmillan Pass, Yukon TerritoryRams-49ers draws 12.29 million for Thursday Night FootballKay Patterson, who rose from janitor at segregated South Carolina capitol to state senator, dies
The New York Yankees have agreed to sign left-handed pitcher Max Fried to an eight-year, $218 million dollar contract -- the largest ever for a left-handed hurler, MLB.com reported Tuesday. The reported deal would be the fourth-largest for any pitcher, a list led by the Los Angeles Dodgers' 10-year, $700 million contract with Japanese superstar Shohei Ohtani. Fried would join right-hander Gerrit Cole in a formidable Yankees rotation. He had an 11-10 record with the Atlanta Braves last season with a 3.25 earned run average in 29 starts. Fried gave up 146 hits and 57 walks with 166 strikeouts for the Braves and tied the Major League Baseball lead with two complete games. The Yankees' reported signing of Fried comes after the club missed out on Dominican superstar Juan Soto, who entered free agency after playing for the Yankees last year but is reportedly headed to the New York Mets on a record-breaking 15-year, $765 million deal. bb/js © Agence France-PresseLG Innotek to Foster the Automotive Car Sensing Business into a USD 1.4 Billion Business by 2030, Led by Its RGB-IR In-Cabin camera module
VANCOUVER — A confidence agreement between British Columbia's New Democrats and the provincial Green Party stabilizes David Eby’s bare-majority government, while putting Green election promises on the legislative agenda. The agreement announced Friday outlines the basis on which the Greens' two-member caucus will provide confidence to Eby's party, which won election with 47 seats in B.C.'s 93-seat legislature in October's provincial election. The deal features key elements of the Greens' election platform, including a commitment to growing a community health centre model for primary care and expanding public coverage of psychology services at a cost of $50 million. Deputy premier Niki Sharma said the framework focuses on areas of agreement between the two parties, while recognizing their positions won't always align. The balance struck is "a way to keep government stable for four years ... without erasing the distinct identity that we both have as political parties," she said Friday. The seven-page agreement says the house leaders of the NDP and the Greens "agree to establish a relationship of trust based on good faith and no surprises." While set to last four years, it is subject to annual agreement at each parties discretion. It was important to the Greens throughout the negotiations to be able to disagree with government positions, Sharma told a news conference. "I know that we'll have differences of opinions moving forward, but the fact that we can show a pathway where two political parties in a time of great polarization can come together for British Columbians, I think is a profound thing." The October election saw two new Green members win seats, lawyer Rob Botterell, representing Saanich North and the Islands, and geological engineer Jeremy Valeriote in West Vancouver-Sea to Sky, while the B.C. Conservatives won 44 seats. B.C. Conservative Leader John Rustad said after the election that he would work to bring the NDP government down if it continues with its "destructive policies." When he was asked about the agreement on Friday, Rustad said he has always assumed the Greens would back the NDP. Eby is "fooling himself" if he thinks having the support of the Green Party is going to make it easier to pass legislation, Rustad said in an interview. "We are going to make it very difficult for him to move anything through the legislature that is continuing the destruction of British Columbia," he said. "A week can be a long time in politics, so we'll see what January brings. I don't want to say anything further at this point." The stability of Eby's government had appeared shakier earlier this month when New Democrat Grace Lore announced she was temporarily stepping away due to a cancer diagnosis, though she said she intended to participate in important votes. Eby said in a statement Friday that the agreement with the Greens will "strengthen the stability of government and help deliver on the priorities of British Columbians." While his party and the Greens are distinct and won't always agree, the premier said they have "many shared values." He said the deal sets out specific areas of action they will work together on, including health care, affordable housing, creating livable communities and growing a strong, sustainable economy. "We will continue to work with all MLAs who want to make the legislature work for people," Eby said. Additional policy commitments outlined in the deal that reflect the Green platform include expanding access to housing aid for elderly renters and building 30,000 more units of non-market housing than the government had pledged. The agreement also commits to a review of B.C.'s forests to "address concerns around sustainability, jobs, environmental protection an the future of the industry." This report by The Canadian Press was first published Dec. 13, 2024. Brenna Owen, The Canadian Press
THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) SOURCE AmgenVANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) — Patagonia Gold Corp. (“Patagonia” or the “Company”) (TSXV: PGDC) announces that it has granted an aggregate of 8,000,000 incentive stock options under the Company’s stock option plan (the “Stock Option Plan”) to the directors of the Company, 3,500,000 incentive stock options to certain officers of the Company and 3,800,000 incentive stock options to members of senior management of the Company as part of a long term incentive plan (the “Option Grant”). All of the Options are exercisable for a period of five years at a price of $0.035. The Options vest as to one-third on each of the first, second and third anniversary of the date of the Option Grant. The Stock Option Plan allows for the issuance of up to 10% of the issued and outstanding shares of the Company in the form of Options. As of the date hereof, a total of 465,051,490 shares of the Company are issued and outstanding and the Option Grant represents approximately 3.3% of the issued and outstanding shares. Patagonia Gold Corp. is a South America focused, publicly traded, mining company listed on the TSX Venture Exchange. The Company seeks to grow shareholder value through exploration and development of gold and silver projects in the Patagonia region of Argentina. The Company is primarily focused on the Calcatreu project in Rio Negro and the development of the Cap-Oeste underground project. Patagonia, indirectly through its subsidiaries or under option agreements, has mineral rights to over 415 properties in several provinces of Argentina and is one of the largest landholders in the province of Santa Cruz, Argentina. Christopher van Tienhoven, Chief Executive Officer Patagonia Gold Corp T: +54 11 5278 6950 E:Prep football Class A final: White Falcons ride ground game to title
Kriti Sanon has been making headlines lately due to her rumoured relationship with UK-based businessman Kabir Bahia. The actress recently celebrated Christmas with Kabir, and photos from their festive gathering quickly went viral on social media, fueling speculation about their romance. In a recent update, Kriti's sister Nupur Sanon took to social media to share pictures and videos from a star-studded event in Dubai, where she and Kriti enjoyed a mesmerising performance by the legendary Rahat Fateh Ali Khan. Joining the Sanon sisters at the event were several other notable celebrities, including singer Stebin Ben, actor Varun Sharma, and Kabir Bahia, who was once again spotted alongside Kriti, further sparking rumors about their relationship status. Pictures from a recent event have surfaced, showcasing Kriti Sanon, Varun Sharma and her sister Nupur Sanon having an absolute blast as they attended a concert by the renowned Pakistani singer Rahat Fateh Ali Khan. The evening was filled with music, laughter and camaraderie, as evident from the photos and videos shared by Nupur on social media. One particular video clip shared by Nupur captures the joyous moment when she, Kriti, Varun and singer Stebin Ben sang along to Rahat Fateh Ali Khan's soulful rendition of the popular song 'Main Tenu Samjhawan Ki'. Kriti looked stunning in a beautiful blue dress, completely immersed in the magic of the music. (Image: Instagram/@thelastshahmurai, @nupursanon) Although Kabir Bahia, Kriti's rumored boyfriend, was not featured in the video clip, Nupur shared another photo that shows her sitting on stage with Stebin, Kabir and another friend. In the photo, Nupur is seen beaming with joy, surrounded by the three men she affectionately referred to as her "main 3 handsome men!" Kabir looked dashing in a black shirt paired with matching pants. The photo has inevitably sparked more speculation about Kriti and Kabir's relationship status. Another picture from the event has surfaced on Instagram, featuring Kriti Sanon, Kabir Bahia, Nupur, cricketer MS Dhoni and several others together on stage, enjoying Stebin Ben's performance. The photo was captioned "A moment to remember," aptly summarising the essence of the evening. Several other pictures from the event have also been shared on Instagram, offering a glimpse into the fun-filled night that was filled with music, friends and celebration.Smodin Unites Powerful Domains to Deliver an All-in-One AI PlatformKey details about the man accused of killing of UnitedHealthcare's CEO
LAS VEGAS (AP) — Trae Young might be the NBA's biggest enigma. Young's fans can point to numbers and say he's an elite player. His detractors can point to numbers and say he's overrated. Both arguments have validity. To some, his cocky ways are endearing. To others, they're infuriating. This can't be argued: He's helping Atlanta author one of the season's surprise stories. The Hawks are in the NBA Cup semifinals, set to play Milwaukee on Saturday before the other semifinal between Oklahoma City and Houston. The title game is Tuesday night. “When we talk about Trae, the word I like to use is evolution,” Hawks coach Quin Snyder said. “And every player evolves. They just evolve in different ways. He's been an important part of our young guys' growth and being able to elevate them.” The Hawks haven't had a ton of big moments in Young's seven seasons. But he has shown a propensity for rising to the occasion: ousting New York in the 2021 playoffs, ousting the Knicks from the quarterfinals of this tournament to get to Las Vegas — and now comes another chance on national TV on Saturday, facing the Bucks with a chance to play for a trophy. “I feel like this team has been embracing the challenge each and every night from the beginning of the season,” Young said. “We haven’t looked too far ahead in any moment. We’re just taking it day by day. Even though early on in the season we may have had some struggles and some bumps in the road and some guys out, we stuck with the process and focus on each day." Here's part of the pro-Young argument: He's averaging 21 points and 12 assists something that only Magic Johnson and Isiah Thomas have done over a full season, and he's on pace to lead the league in assist average for the first time. Here's part of the anti-Young argument: Among the 220 players with at least 50 3-point attempts this season he ranks 189th at 30.8%, and of the 248 players with at least 100 field goal attempts this season he ranks 231st at 38.4%. Choose your side. They're both valid. But it's clear that Young — who made no secret that he was upset over not being picked for the team that won gold for USA Basketball at the Paris Olympics this past summer — is growing and maturing. “He’s doing a better job on both ends of the floor,” Bucks coach Doc Rivers said. “Defensively he’s figured out a way of keeping himself out of actions. I know that sounds easy. That’s hard to do, and he’s brilliant at it, he really is. ... He must be really studying the game on both ends of the floor, and you can see that in his play. And he’s earned the trust of his players. This team likes playing with him, that’s obvious. I couldn’t say that in the past, but now they love playing with him.” Hawks forward Jalen Johnson doesn't deny that point. “He’s so good, man,” Johnson said. "It’s crazy, like just seeing it in person and on TV prior to me playing with the Hawks and getting drafted by the Hawks, it was crazy just watching it. A guy that’s undersized, being able to score at will, being able to make any pass at will. And then next thing you know you’re his teammate and you’re on the receiving end of those passes. “Watching those clutch late game buckets, it’s a joy to watch. It’s a gift that he has that’s very special and not many people have had it at that elite of a level. It’s been great being his teammate. It’s been a blessing.” Saturday is an opportunity. The semifinals are the only games on the NBA calendar for that day; the title game Tuesday — which doesn't count in the standings — is the only game on the NBA slate that night as well. Young will have tons of eyeballs on him Saturday and would have tons more on him Tuesday if the Hawks find a way to win another big game against the Bucks. They're 3-1 against Eastern Conference-leading Cleveland and Boston already this season, 1-0 against Milwaukee. The potential is clear for the Hawks. The potential for Young has always been clear as well. Only now, it's starting to be realized. “The narrative about me not being able to do certain things or being too mad or frustrated about certain things is — I mean, just aren’t true,” Young said. "I think you’re just now being able to see like with the young team we have, just some of the different things we’ve been doing this year, I think just now you’re starting to kind of see it because the results are showing and we’re winning now. We’re here in this final four of the Cup, and it’s a big deal.” AP NBA: https://apnews.com/hub/NBA